You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids

    SBC: SEACOAST SCIENCE, INC.            Topic: NIDA

    AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. A novel role for Reelin therapeutics in inflammatory bowel disease

    SBC: REELIN THERAPEUTICS, INC.            Topic: 300

    Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A platform for engineering peptide ligase for building next generation peptide therapeutics.

    SBC: SCRIBE BIOSCIENCES, INC.            Topic: 400

    PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging

    SBC: PETcoil, Inc.            Topic: 101

    Project Summary Medical imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used in studying the underlying mechanisms of mental illnesses and neurological disorders such as brain tumors, Alzheimer’s disease, epilepsy, and depression, etc. However, PET and MRI scans are almost always ordered as separate studies on separate machine ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A Vaccine for Acute Flaccid Myelitis

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYIn 2014 the United States experienced an outbreak of a previously unknown neurological disease with polio-like symptoms later known as acute flaccid myelitis (AFM). A biennial surge in cases of AFM in 2016 and 2018 has alarmed public health officials. Since then, rapidly accumulating clinical, immunological, and epidemiological evidence has pointed to EV-D68 as the major causative agent of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Bounding generalization risk for Deep Neural Networks

    SBC: Euler Scientific            Topic: NGA20A001

    Deep Neural Networks have become ubiquitous in the modern analysis of voluminous datasets with geometric symmetries. In the field of Particle Physics, experiments such as DUNE require the detection of particle signatures interacting within the detector, with analyses of over a billion 3D event images per channel each year; with typical setups containing over 150,000 different channels.  In an ...

    STTR Phase I 2020 Department of DefenseNational Geospatial-Intelligence Agency
  8. Chemically controlling chromatin to treat Friedriech's Ataxia

    SBC: Epigenos Bioscience, Inc.            Topic: NCATS

    We recently developed a technology that combines catalytically inactive dCas9 with bifunctional chemicals that link endogenous host cellular machinery to specific genes targeted with dCas9. We have demonstrated this technology can significantly increase gene expression at multiple endogenous mammalian genes in a chemically dependent manner. Here we propose to apply this technology to the mono-alle ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD

    SBC: SAMAY, INC.            Topic: NHLBI

    ABSTRACTChronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or “flare up” of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or pre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Continuum Actuated Redundant Tendon Robots

    SBC: OPTERUS RESEARCH AND DEVELOPMENT, INC            Topic: HR001119S003523

    Opterus Research and Development, Inc. (Opterus) and Colorado State University (CSU) have combined the best features of high strain composites (HSC), continuum robots, and tendon actuated robots to develop a new concept called Continuum Actuated Redundant Tendon (CART) Robot to enable self-reconfigurable modular robots that can perform various tasks (e.g., walking, crawling, wheeling, and grasping ...

    STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency
US Flag An Official Website of the United States Government